Canadian health news — a new option is opening up for Canadians living with hereditary angioedema. CSL Canada announced this week that access to ANDEMBRY (garadacimab-gxsz) is expanding across the country, with the first patients now receiving the treatment. Quebec became the first public drug plan to list it on July 30, Alberta followed on September 1, and it is also being reimbursed through the federal Non-Insured Health Benefits program and Veterans Affairs Canada — a coverage map that is widening by the month.
By Maplestime News Desk | Winnipeg, Manitoba | September 24, 2026
Sources: CSL | BioSpace | Last updated: September 24, 2026
Key Takeaways
- ANDEMBRY (garadacimab-gxsz) is the first and only once-monthly treatment targeting activated factor XII (FXIIa) for routine prevention of hereditary angioedema attacks in Canada.
- It is indicated for adults and pediatric patients 12 years and older, and received Health Canada market authorization in 2025.
- Quebec’s RAMQ listed it July 30, 2026 — the first public plan in Canada — followed by Alberta on September 1; NIHB and Veterans Affairs Canada are also reimbursing it.
- An estimated 2,500 Canadians live with HAE, a rare genetic disorder that causes sudden, painful swelling attacks.
- Dr. Christine McCusker of McGill: “I now have a once-monthly option to offer my patients that is backed by real-world experience.”
What HAE does — and what this changes
Hereditary angioedema is a rare genetic disorder in which the body produces too little of a protein that keeps blood vessel walls stable. The result: sudden, unpredictable swelling attacks — hands, feet, face, airways, the gastrointestinal tract — that can be disfiguring, agonizing, and in the case of laryngeal attacks, life-threatening. For the roughly 2,500 Canadians living with it, “routine prevention” is not a luxury; it is the difference between planning your life and bracing for the next attack.
Garadacimab is a monoclonal antibody that inhibits activated factor XII, a protein high up in the chain reaction that triggers these attacks. One injection a month, at home — a meaningful simplification for patients and caregivers.
The coverage map is the story
A drug approval means little if patients cannot afford the drug. That is why the reimbursement news matters as much as the science: Quebec’s public plan moved first in July, Alberta followed this month, and federal coverage through NIHB and Veterans Affairs extends access to Indigenous patients and veterans. CSL says it is working with remaining provinces and territories — the usual slow, province-by-province grind of Canadian drug access.
“I now have a once-monthly option to offer my patients that is backed by real-world experience,” said Dr. Christine McCusker, the McGill immunologist who has treated HAE patients for years. For a community that measures progress in decades, two provinces and two federal programs in two months is momentum.
The question now is how fast the rest of the country follows. For HAE patients in provinces still waiting, “coming soon” has a very personal meaning.
Photo credits: James Gathany / CDC (Public domain); Wikimedia Commons / Matanbz (CC BY-SA 4.0); Wikimedia Commons / Spudgun67 (CC BY-SA 4.0).
Enjoying Maplestime? Support independent Canadian journalism — no paywall, no corporate owners.
